on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech SA: Provision of financial documents
Sartorius Stedim Biotech Group has announced the availability of financial results for the first half of 2024. Investors can access detailed information via the following link:
https://www.sartorius.com/en/company-fr/investor-relations-fr/sartorius-stedim-biotech-sa-investor-relations-fr
The documents posted online include business development for the period January to June 2024 as well as forecasts for the year. The consolidated accounts for the period ended June 30, 2024 are also available.
The company, based in Aubagne, is an international leader in the biopharmaceutical field. Listed on Euronext Paris, Sartorius Stedim Biotech provides solutions for the manufacturing of biotechnological medicines. In 2023, the group achieved a turnover of 2.8 billion euros and currently employs 10,600 people around the world.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news